Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Beasley, CM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 61 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Brunswick, DJ; Amsterdam, JD; Fawcett, J; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Beasley, CM
      Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    2. Czekalla, J; Beasley, CM; Dellva, MA; Berg, PH; Grundy, S
      Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis

      JOURNAL OF CLINICAL PSYCHIATRY
    3. Czekalla, J; Kollack-Walker, S; Beasley, CM
      Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics

      JOURNAL OF CLINICAL PSYCHIATRY
    4. McGrath, PJ; Stewart, JW; Petkova, E; Quitkin, FM; Amsterdam, JD; Fawcett, J; Reimherr, FW; Rosenbaum, JF; Beasley, CM
      Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression

      JOURNAL OF CLINICAL PSYCHIATRY
    5. Beasley, CM; Nilsson, ME; Koke, SC; Gonzales, JS
      Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose

      JOURNAL OF CLINICAL PSYCHIATRY
    6. Beasley, CM; Koke, SC; Nilsson, ME; Gonzales, JS
      Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis

      CLINICAL THERAPEUTICS
    7. Revicki, DA; Genduso, LA; Hamilton, SH; Ganoczy, D; Beasley, CM
      Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial

      QUALITY OF LIFE RESEARCH
    8. Hudson, MF; Beasley, CM; Benedict, RH; Carlson, JR; Craig, BF; Mason, SC
      Elder abuse - Some African American views

      JOURNAL OF INTERPERSONAL VIOLENCE
    9. Callaghan, JT; Bergstrom, RF; Ptak, LR; Beasley, CM
      Olanzapine - Pharmacokinetic and pharmacodynamic profile

      CLINICAL PHARMACOKINETICS
    10. Perry, PJ; Sanger, T; Beasley, CM
      Plasma olanzapine and clinical response: Reply

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    11. Zajecka, J; Amsterdam, JD; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Tamura, RN; Sundell, KL; Michelson, D; Beasley, CM
      Changes in adverse events reported by patients during 6 months of fluoxetine therapy

      JOURNAL OF CLINICAL PSYCHIATRY
    12. Beasley, CM
      Olanzapine and tardive dyskinesia - Author's reply

      BRITISH JOURNAL OF PSYCHIATRY
    13. Tran, PV; Tollefson, GD; Sanger, TM; Lu, YL; Berg, PH; Beasley, CM
      Olanzapine versus haloperidol in the treatment of schizoaffective disorder- Acute and long-term therapy

      BRITISH JOURNAL OF PSYCHIATRY
    14. Beasley, CM; Dellva, MA; Tamura, RN; Morgenstern, H; Glazer, WM; Ferguson, K; Tollefson, GD
      Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

      BRITISH JOURNAL OF PSYCHIATRY
    15. Beasley, CM
      Response to letter of Professor Tim Lambert

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
    16. Michelson, D; Amsterdam, JD; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Zajecka, J; Sundell, KL; Kim, Y; Beasley, CM
      Changes in weight during a 1-year trial of fluoxetine

      AMERICAN JOURNAL OF PSYCHIATRY
    17. BEASLEY CM
      SUICIDALITY WITH FLUOXETINE

      CNS DRUGS
    18. BEASLEY CM; SAYLER ME; KIESLER GM; POTVIN JH; SANGER TM; TOLLEFSON GD
      THE INFLUENCE OF PHARMACOTHERAPY ON SELF-DIRECTED AND EXTERNALLY-DIRECTED AGGRESSION IN SCHIZOPHRENIA

      Schizophrenia research
    19. REAMS SG; SANGER TM; BEASLEY CM
      OLANZAPINE IN THE TREATMENT OF ELDERLY PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS

      Schizophrenia research
    20. TAMURA RN; BEASLEY CM; DELLVA MA; GLAZER WM; MORGENSTERN H; TOLLEFSON GD
      WHAT IS THE DIFFERENTIAL RISK OF TARDIVE-DYSKINESIA WITH THE NOVEL ANTIPSYCHOTIC OLANZAPINE

      Schizophrenia research
    21. JONES B; CRAWFORD AMK; BEASLEY CM; TOLLEFSON GD
      THE ACUTE AND LONG-TERM EFFECT OF OLANZAPINE COMPARED WITH PLACEBO AND HALOPERIDOL ON SERUM PROLACTIN CONCENTRATION

      Schizophrenia research
    22. WRIGHT P; TOLLEFSON GD; BEASLEY CM; TAMURA RN; TRAN PV; POTVIN JII
      A BLINDED, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT - EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL

      Schizophrenia research
    23. HAMILTON SH; REVICKI DA; GENDUSO LA; BEASLEY CM
      OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - QUALITY-OF-LIFE AND EFFICACY RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND TRIAL

      Neuropsychopharmacology
    24. HUDSON MF; ARMACHAIN WD; BEASLEY CM; CARLSON JR
      ELDER ABUSE - 2 NATIVE-AMERICAN VIEWS

      The Gerontologist
    25. TRAN PV; DELLVA MA; TOLLEFSON GD; WENTLEY AL; BEASLEY CM
      ORAL OLANZAPINE VERSUS ORAL HALOPERIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES

      British Journal of Psychiatry
    26. TOLLEFSON GD; SANGER TM; BEASLEY CM; TRAN PV
      A DOUBLE-BLIND, CONTROLLED COMPARISON OF THE NOVEL ANTIPSYCHOTIC OLANZAPINE VERSUS HALOPERIDOL OR PLACEBO ON ANXIOUS AND DEPRESSIVE SYMPTOMS ACCOMPANYING SCHIZOPHRENIA

      Biological psychiatry
    27. MICHELSON D; TAMURA R; SUNDELL K; BEASLEY CM
      EARLY AND LATE ADVERSE EVENT PROFILES ASSOCIATED WITH FLUOXETINE TREATMENT

      Biological psychiatry
    28. REIMHERR FW; AMSTERDAM JD; QUITKIN FM; ROSENBAUM JF; FAVA M; ZAJECKA J; BEASLEY CM; MICHELSON D; ROBACK P; SUNDELL K
      OPTIMAL LENGTH OF CONTINUATION THERAPY IN DEPRESSION - A PROSPECTIVE ASSESSMENT DURING LONG-TERM FLUOXETINE TREATMENT

      The American journal of psychiatry
    29. AMSTERDAM JD; FAWCETT J; QUITKIN FM; REIMHERR FW; ROSENBAUM JF; MICHELSON D; BEASLEY CM
      FLUOXETINE AND NORFLUOXETINE - DR. AMSTERDAM AND COLLEAGUES REPLY

      The American journal of psychiatry
    30. TOLLEFSON GD; BEASLEY CM; KUNTZ AJ
      OLANZAPINE ON TRIAL - REPLY

      The American journal of psychiatry
    31. DELLVA MA; TRAN P; TOLLEFSON GD; WENTLEY AL; BEASLEY CM
      STANDARD OLANZAPINE VERSUS PLACEBO AND INEFFECTIVE DOSE OLANZAPINE INTHE MAINTENANCE TREATMENT OF SCHIZOPHRENIA

      Psychiatric services
    32. BEASLEY CM; HAMILTON SH; CRAWFORD AM; DELLVA MA; TOLLEFSON GD; TRAN PV; BLIN O; BEUZEN JN
      OLANZAPINE VERSUS HALOPERIDOL - ACUTE-PHASE RESULTS OF THE INTERNATIONAL DOUBLE-BLIND OLANZAPINE TRIAL

      European neuropsychopharmacology
    33. CRAWFORD AMK; BEASLEY CM; TOLLEFSON GD
      THE ACUTE AND LONG-TERM EFFECT OF OLANZAPINE COMPARED WITH PLACEBO AND HALOPERIDOL ON SERUM PROLACTIN CONCENTRATIONS

      Schizophrenia research
    34. TOLLEFSON GD; LU YL; SANGER TM; BEASLEY CM; TRAN PV
      OLANZAPINE IN THE TREATMENT OF SCHIZOAFFECTIVE DISORDER

      Schizophrenia research
    35. TOLLEFSON GD; SANGER TM; BEASLEY CM
      THE COURSE OF PRIMARY AND SECONDARY NEGATIVE SYMPTOMS IN A CONTROLLEDTRIAL WITH OLANZAPINE

      Schizophrenia research
    36. BEASLEY CM
      UNTITLED - RESPONSE

      Neuropsychopharmacology
    37. TRAN PV; DELLVA MA; TOLLEFSON GD; BEASLEY CM; POTVIN JH; KIESLER GM
      EXTRAPYRAMIDAL SYMPTOMS AND TOLERABILITY OF OLANZAPINE VERSUS HALOPERIDOL IN THE ACUTE TREATMENT OF SCHIZOPHRENIA

      The Journal of clinical psychiatry
    38. BEASLEY CM; TOLLEFSON GD; TRAN PV
      EFFICACY OF OLANZAPINE - AN OVERVIEW OF PIVOTAL CLINICAL-TRIALS

      The Journal of clinical psychiatry
    39. BEASLEY CM; TOLLEFSON GD; TRAN PV
      SAFETY OF OLANZAPINE

      The Journal of clinical psychiatry
    40. BLUMENFIELD M; LEVY NB; SPINOWITZ B; CHARYTAN C; BEASLEY CM; DUBEY AK; SOLOMON RJ; TODD R; GOODMAN A; BERGSTROM RF
      FLUOXETINE IN DEPRESSED-PATIENTS ON DIALYSIS

      International journal of psychiatry in medicine
    41. TOLLEFSON GD; BEASLEY CM; TAMURA RN; TRAN PV; POTVIN JH
      BLIND, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT-EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL

      The American journal of psychiatry
    42. AMSTERDAM JD; FAWCETT J; QUITKIN FM; REIMHERR FW; ROSENBAUM JF; MICHELSON D; HORNIGROHAN M; BEASLEY CM
      FLUOXETINE AND NORFLUOXETINE PLASMA-CONCENTRATIONS IN MAJOR DEPRESSION - A MULTICENTER STUDY

      The American journal of psychiatry
    43. TOLLEFSON GD; BEASLEY CM; TRAN PV; STREET JS; KRUEGER JA; TAMURA RN; GRAFFEO KA; THIEME ME
      OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE AND SCHIZOPHRENIFORM DISORDERS - RESULTS OF AN INTERNATIONAL COLLABORATIVE TRIAL

      The American journal of psychiatry
    44. TOLLEFSON GD; BEASLEY CM; TRAN PV; TAMURA RN; SANGER TM; WOOD A; BEUZEN JN
      OLANZAPINE VERSUS HALOPERIDOL - RESULTS OF THE MULTICENTER INTERNATIONAL TRIAL

      Schizophrenia research
    45. BEASLEY CM; TOLLEFSON G; TRAN P; SATTERLEE W; SANGER T; HAMILTON S; FABRE L; SMALL J; ERESHEFSKY L; TRUE J; NEMEROFF C; RISCH SC; PERRY PJ; POTKIN SG; BORISON RL; JAMES S; MELTZER HY; IQBAL N; FANN WE; GEWIRTZ GR; LANDBLOOM R; ROYBYRNE PP; TUASON VB; CARMAN JS; STOKES PE; WILLIAMS R; ANCILL RJ; MACEWAN GW; GUJAVARTY KS; JONES B; LOHR JB
      OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - ACUTE-PHASE RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND OLANZAPINE TRIAL

      Neuropsychopharmacology
    46. LEVY NB; BLUMENFIELD M; BEASLEY CM; DUBEY AK; SOLOMON RJ; TODD R; GOODMAN A; BERGSTROM RR
      FLUOXETINE IN DEPRESSED-PATIENTS WITH RENAL-FAILURE AND IN DEPRESSED-PATIENTS WITH NORMAL KIDNEY-FUNCTION

      General hospital psychiatry
    47. LEVY NB; BLUMENFIELD M; BEASLEY CM; DUBEY AK; SOLOMON RJ; TODD R; GOODMAN A; BERGSTROM RF
      FLUOXETINE IS SAFE AND EFFICACIOUS IN DEPRESSED HEMODIALYSIS-PATIENTS

      Psychosomatics
    48. BEASLEY CM; SANGER T; SATTERLEE W; TOLLEFSON G; TRAN P; HAMILTON S; GREEN A; DOTT S; PFISTER G; ROXAS L; SMALL J; THOMAS M; AMES D; SCHOOLER N; BAKER R; LEVINE R; FABRE L; FRIEDEL R; SAFFERMAN A; LIEBERMAN J; STAHL S
      OLANZAPINE VERSUS PLACEBO - RESULTS OF A DOUBLE-BLIND, FIXED-DOSE OLANZAPINE TRIAL

      Psychopharmacology
    49. TRAN PV; BEASLEY CM; TOLLEFSON GD; BEUZEN JN; HOLMAN SL; SANGER TM; SATTERLEE WG
      OLANZAPINE - A PROMISING ATYPICAL ANTIPSYCHOTIC AGENT

      Schizophrenia research
    50. GOLDSTEIN DJ; HAMILTON SH; MASICA DN; BEASLEY CM
      FLUOXETINE IN DEPRESSED GERIATRIC-PATIENTS - EFFECT ON WEIGHT

      Clinical pharmacology and therapeutics
    51. AMSTERDAM JD; HORNIGROHAN M; ROSENBAUM JF; QUITKIN FM; FAWCETTE J; REIMHERR FW; BEASLEY CM
      FLUOXETINE AND NORFLUOXETINE PLASMA-LEVELS IN MAJOR DEPRESSION

      Biological psychiatry
    52. HARRISON DA; SATTERLEE W; TRAN P; BEASLEY CM; TOLLEFSON GD
      OLANZAPINE - A POTENTIAL ATYPICAL ANTIPSYCHOTIC AGENT - PHASE-II CLINICAL FINDINGS

      Schizophrenia research
    53. TOLLEFSON GD; RAMPEY AH; BEASLEY CM; ENAS GG; POTVIN JH
      ABSENCE OF A RELATIONSHIP BETWEEN ADVERSE EVENTS AND SUICIDALITY DURING PHARMACOTHERAPY FOR DEPRESSION

      Journal of clinical psychopharmacology
    54. BEASLEY CM
      FLUOXETINE-DOPAMINERGIC INTERACTION DATA

      The Journal of clinical psychiatry
    55. TOLLEFSON GD; BEASLEY CM; TRAN PV; SANGER T
      OLANZAPINE - A NOVEL ANTIPSYCHOTIC WITH A BROAD-SPECTRUM PROFILE

      Biological psychiatry
    56. BEASLEY CM; MASICA DN; HEILIGENSTEIN JH; WHEADON DE; ZERBE RL
      POSSIBLE MONOAMINE-OXIDASE INHIBITOR SEROTONIN UPTAKE INHIBITOR INTERACTION - FLUOXETINE CLINICAL-DATA AND PRECLINICAL FINDINGS

      Journal of clinical psychopharmacology
    57. BERGSTROM RF; BEASLEY CM; LEVY NB; BLUMENFIELD M; LEMBERGER L
      THE EFFECTS OF RENAL AND HEPATIC-DISEASE ON THE PHARMACOKINETICS, RENAL TOLERANCE, AND RISK-BENEFIT PROFILE OF FLUOXETINE

      International clinical psychopharmacology
    58. BEASLEY CM; POTVIN JH
      FLUOXETINE - ACTIVATING AND SEDATING EFFECTS

      International clinical psychopharmacology
    59. HEILIGENSTEIN JH; BEASLEY CM; POTVIN JH
      FLUOXETINE NOT ASSOCIATED WITH INCREASED AGGRESSION IN CONTROLLED CLINICAL-TRIALS

      International clinical psychopharmacology
    60. BEASLEY CM; SAYLER ME; POTVIN JH
      FLUOXETINE VERSUS AMITRIPTYLINE IN THE TREATMENT OF MAJOR DEPRESSION - A MULTICENTER TRIAL

      International clinical psychopharmacology
    61. GOLDSTEIN DJ; RAMPEY AH; POTVIN JH; MASICA DN; BEASLEY CM
      ANALYSES OF SUICIDALITY IN DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OFPHARMACOTHERAPY FOR WEIGHT-REDUCTION

      The Journal of clinical psychiatry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 23:33:29